2004
DOI: 10.1002/jps.10533
|View full text |Cite
|
Sign up to set email alerts
|

Polymer–drug compatibility: A guide to the development of delivery systems for the anticancer agent, ellipticine

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
247
0
1

Year Published

2008
2008
2022
2022

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 327 publications
(251 citation statements)
references
References 33 publications
3
247
0
1
Order By: Relevance
“…According to LIU et al (2004) the presence of shifts or changes in the polymer-drug spectrum is an indication that they are chemically interacting. DEV et al (2010) encapsulated lamivudine in PLA and chitosan nanoparticles and compared the FTIR spectra of black nanoparticles to nanoparticles containing the drug.…”
Section: Resultsmentioning
confidence: 99%
“…According to LIU et al (2004) the presence of shifts or changes in the polymer-drug spectrum is an indication that they are chemically interacting. DEV et al (2010) encapsulated lamivudine in PLA and chitosan nanoparticles and compared the FTIR spectra of black nanoparticles to nanoparticles containing the drug.…”
Section: Resultsmentioning
confidence: 99%
“…Peaks corresponding to the melting endotherm of pure famotidine, pure TKP and xanthan were observed on the DSC thermograms of crushed tablets ( Figure 7) and there was no significant change in melting point of the drug and powders in crushed tablets and no other appreciable peak was observed. This indicated that there was no interaction between famotidine and the polymers, meaning that the drug and the polymers were compatible [26].…”
Section: Evaluation Of Prepared Matrix Tabletsmentioning
confidence: 99%
“…Achievement of this high drug loading level highlights the influence of drug-excipient compatibility as demonstrated in previous studies. 41 Over 30 days, the GA-mPEG 2000 micelle solution remained clear and transparent, and the average size and PDI did not change significantly (Figure 3). Therefore, conjugating gambogic acid with biocompatible water-soluble mPEG 2000 resulted in a homogeneous and stable dosage form in aqueous solution with high drug loading and a small particle size, which makes gambogic acid more suitable for intravenous administration.…”
Section: Discussionmentioning
confidence: 98%